	US 11,851,484 B2
	Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
Natalia Arenas-Ramirez, Zürich (CH); Iwan Beuvink, Basel (CH); Onur Boyman, Küsnacht (CH); Barbara Brannetti, Basel (CH); Andreas Katopodis, Basel (CH); Simone Popp, Basel (CH); Catherine Regnier, Basel (CH); and Chao Zou, Basel (CH)
Assigned to UNIVERSITÄT ZÜRICH, Zürich (CH)
Filed by Universität Zürich, Zürich (CH)
Filed on Dec. 17, 2020, as Appl. No. 17/124,930.
Application 17/124,930 is a continuation of application No. 16/069,146, granted, now 10,889,643, previously published as PCT/IB2017/050127, filed on Jan. 11, 2017.
Claims priority of provisional application 62/277,113, filed on Jan. 11, 2016.
Prior Publication US 2021/0246200 A1, Aug. 12, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); C07K 14/55 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 16/246 (2013.01) [C07K 14/55 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/74 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01)]

21 Claims

1. An antibody/IL-2 fusion protein comprising:

an antibody comprising a light chain (LC), a heavy chain (HC), and a human interleukin-2 protein (hIL-2) polypeptide inserted, directly or through a linker, within at least one of its six complementarity determining regions (CDRs), wherein the amino acid sequence of the original CDRs, comprise HC-CDRs of SEQ ID NOs: 119, 120, and 121, respectively, and LC-CDRs of SEQ ID NOs: 122, 123, and 21, respectively; and wherein said antibody/IL-2 fusion protein has hIL-2 activity.